Ekso Bionics (NASDAQ:EKSO) Rating Increased to Buy at ValuEngine

Ekso Bionics (NASDAQ:EKSO) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.

Shares of Ekso Bionics stock traded down $0.20 during trading hours on Thursday, hitting $0.95. The company’s stock had a trading volume of 1,828,372 shares, compared to its average volume of 254,222. The stock has a 50 day moving average price of $1.25. Ekso Bionics has a 12-month low of $0.87 and a 12-month high of $3.30. The firm has a market cap of $89.03 million, a P/E ratio of -2.15 and a beta of 1.44. The company has a current ratio of 1.73, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.04) EPS for the quarter. Ekso Bionics had a negative net margin of 206.32% and a negative return on equity of 501.28%. The business had revenue of $3.26 million during the quarter.

Several institutional investors have recently made changes to their positions in the company. Wilbanks Smith & Thomas Asset Management LLC bought a new position in Ekso Bionics during the 1st quarter valued at approximately $25,000. Pinnacle Associates Ltd. bought a new position in Ekso Bionics during the 1st quarter valued at approximately $60,000. PHH Investments Ltd. increased its holdings in shares of Ekso Bionics by 10.3% in the 1st quarter. PHH Investments Ltd. now owns 53,762 shares of the company’s stock worth $135,000 after purchasing an additional 5,000 shares in the last quarter. Spark Investment Management LLC bought a new stake in shares of Ekso Bionics in the 1st quarter worth $80,000. Finally, Bailard Inc. bought a new stake in shares of Ekso Bionics in the 1st quarter worth $63,000. Institutional investors and hedge funds own 32.79% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.

Featured Article: Why does the United States have a lingering trade deficit?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.